Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2000
08/29/2000US6110924 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
08/29/2000US6110923 Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
08/29/2000US6110922 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
08/29/2000US6110921 Administering to mammal a sustained-release microparticle comprising antipsychotic agent in biodegradable polymer matrix
08/29/2000US6110920 Treatment of cardiovascular disorders and impotency
08/29/2000US6110919 Diazabicyclic neurokinin antagonists
08/29/2000US6110918 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
08/29/2000US6110917 Selective serotonin (5-ht) receptor agonist for treating migraines, vasospasms
08/29/2000US6110915 Antiemetic use of triazolo-pyridazine derivatives
08/29/2000US6110914 Spiroazabicyclic heterocyclic compounds
08/29/2000US6110913 N-substituted azaheterocyclic carboxylic acids and esters thereof
08/29/2000US6110912 Administering to eye of patient a serine-threonine kinase inhibitor to enhance aqueous humor outflow
08/29/2000US6110910 Antiinflammatory agents, antiarthritic agents, antirheumatic agents, anticarcinogenic agents
08/29/2000US6110908 Skin sensitive mixture of antimicrobial lower alkanol, antimicrobial fatty acid or glycerol monolaurate, and zinc pyrithione
08/29/2000US6110906 Androgen derivatives for use in the inhibition of sex steroid activity
08/29/2000US6110905 Long-acting oxytetracycline composition
08/29/2000US6110903 Benzimidazole inhibitors of fructose 1,6-bisphosphatase
08/29/2000US6110900 Nucleic acid ligands
08/29/2000US6110888 Substituted phenols as fragrance, flavor and antimicrobial compounds
08/29/2000US6110742 Nucleotide sequences of nuclease resistant antisense agent which modulates acetylcholinesterase production in the central nervous system; treatment of alzheimer's disease with reduced side effects
08/29/2000US6110740 Human vault RNA
08/29/2000US6110716 HIV integrase inhibitors
08/29/2000US6110672 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
08/29/2000US6110505 Translucent antacid suspension containing co-dried dihydroxy aluminum sodium carbonate
08/29/2000US6110504 A crystalloid solution consisting of dissolved salts comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride and organic acid selected from lactate, acetate, pyruvate, gluconate, succinate, and glucose
08/29/2000US6110503 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
08/29/2000US6110502 Method for producing water dispersible sterol formulations
08/29/2000US6110499 Phenytoin therapy
08/29/2000US6110497 Pharmaceutical formulations
08/29/2000US6110494 The mini-tablets which release cisapride or its salt in a controlled manner in the distal regions of gastrointestinal tract have a core of cisapride or a salt embedded in a hydrophilic polymer coated with a ph dependent polymer
08/29/2000US6110493 Terazosin capsules
08/29/2000US6110489 Use of quinolines and quinolones to treat male erectile dysfunction
08/29/2000US6110485 Includes a therapeutical agent and retanoid along with a carrier sized for insertion into eye tissue in which the systemic release of a therapeutical agent is desired for providing sustained or controlled release of the drug
08/29/2000US6110478 Oral carotenoid of carotene compounds
08/29/2000US6110477 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
08/29/2000US6110475 Compostion, barrier film, and method for preventing contact dermatitis
08/29/2000US6110471 Administering phosphodiesterase for inhibition of the cycles
08/29/2000US6110460 Methods of using morphogen analogs
08/29/2000US6110458 Cancer therapy utilizing ex vivo gene transduction
08/29/2000US6110453 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
08/29/2000US6110449 Antiperspirant, perfumes, cyclodextrin inclusion complex andcarriers
08/29/2000CA2157879C Methods for inhibiting bone loss with 3,4-diarylchroman
08/29/2000CA2086754C Treatment of human lactation failure
08/29/2000CA2018704C N-phenylpyrazole derivatives
08/29/2000CA2016631C Substituted aminoalkylphosphinic acids
08/29/2000CA2012628C New fluoro-4 benzoic derivatives, process for their preparation and pharmaceutical compositions containing them
08/29/2000CA2012081C 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives
08/26/2000CA2298877A1 Use of mesophase-stabilized compositions for delivery of cholesterol-reducing sterols and stanols in food products
08/24/2000WO2000049413A2 Rapid assay for arthropod-borne disease vectors and pathogens
08/24/2000WO2000049403A1 Method for screening compound having affinity for vitamin d receptor
08/24/2000WO2000049160A1 Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
08/24/2000WO2000049147A1 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
08/24/2000WO2000049144A2 Pyk2 binding proteins
08/24/2000WO2000049135A2 Substrate for cell growth
08/24/2000WO2000049040A2 Antimicrobial/endotoxin neutralizing polypeptide
08/24/2000WO2000049037A1 Growth hormone secretagogues
08/24/2000WO2000049030A1 5-fluorouridine derivatives and anticancer agents containing the same as the active ingredient
08/24/2000WO2000049026A1 Novel process for preparing alendronic acid
08/24/2000WO2000049021A2 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
08/24/2000WO2000049018A1 2-amino-6-anilino-purines and their use as medicaments
08/24/2000WO2000049015A1 Pyridine compounds and their pharmaceutical use
08/24/2000WO2000049014A1 Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
08/24/2000WO2000049011A1 Prothease inhibitors
08/24/2000WO2000049007A1 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
08/24/2000WO2000049005A1 Bicyclic compounds and their use as integrin receptor ligands
08/24/2000WO2000049000A1 Dopamine d1 receptor agonist compounds
08/24/2000WO2000048996A2 β-ALANINE DERIVATIVES
08/24/2000WO2000048994A1 Thioamide derivatives
08/24/2000WO2000048992A1 Acylated aminoacetonitriles as cysteine protease inhibitors
08/24/2000WO2000048989A1 Mevinolin derivatives
08/24/2000WO2000048988A1 Phenylalaninol derivatives
08/24/2000WO2000048987A1 Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
08/24/2000WO2000048983A1 Soluble double metal salt of group ia and iia of (-) hydroxycitric acid
08/24/2000WO2000048636A1 Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
08/24/2000WO2000048634A1 Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
08/24/2000WO2000048632A1 Novel redox clamping agents and uses thereof
08/24/2000WO2000048631A2 Adjuvant and cell maturation agent
08/24/2000WO2000048629A1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS
08/24/2000WO2000048628A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response
08/24/2000WO2000048623A1 Novel amide derivatives as growth hormone secretagogues
08/24/2000WO2000048617A2 Connective tissue softening
08/24/2000WO2000048610A1 Chemical compounds
08/24/2000WO2000048609A1 Chemical compounds
08/24/2000WO2000048608A1 Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside rb¿1?
08/24/2000WO2000048607A1 Directly compressible matrix for controlled release of single daily doses of clarithromycin
08/24/2000WO2000048606A1 Compositions and methods for use in targeting vascular destruction
08/24/2000WO2000048605A1 Agent acting on the hypothalamus and the pituitary gland and having an action on the sexual cycle of domestic animals, and variants
08/24/2000WO2000048604A1 Utilization of dienogest in high doses
08/24/2000WO2000048603A1 DIBENZO-AZEPINE DERIVATIVES AS αV INTEGRIN RECEPTOR ANTAGONISTS
08/24/2000WO2000048602A1 Intermittent claudication therapeutic drugs comprising pyrroloazepines
08/24/2000WO2000048601A1 Medicament for treating hypertension
08/24/2000WO2000048600A1 Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
08/24/2000WO2000048599A1 Use of desoxypeganine in the treatment of alzheimer's dementia
08/24/2000WO2000048598A1 Therapeutic aqueous composition containing a hexahydro-5-pyrimidinamine compound and a polyalkoxylated fatty alcohol
08/24/2000WO2000048597A1 Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
08/24/2000WO2000048596A1 Soluble forms of amoxicillin and treatment of animals
08/24/2000WO2000048594A1 Use of lipoic acid combination with ascorbic acid in the treatment of cancer
08/24/2000WO2000048593A1 Epoxide hydrolase complexes and methods therewith
08/24/2000WO2000048592A1 Essential fatty acids in the prevention of cardiovascular events
08/24/2000WO2000048591A1 Combinations for the treatment of diseases involving angiogenesis